1 insider has bought $50k of Aclarion, Inc. shares across 1 disclosed dealing since August 2026.
| Aug 13, 2026 | Bond Ryan — director | $50,059 |
Aclarion, Inc. is classed as health care. By value disclosed, that ranks 44th of the 44 health care companies where insiders bought in the last twelve months.
Companies with a comparable amount of disclosed buying: MSA Safety Inc · PALISADE BIO, INC. · electroCore, Inc. · Indivior Pharmaceuticals, Inc. · Anixa Biosciences Inc · Amylyx Pharmaceuticals, Inc.
See also the biggest buys, cluster buying and the most-active companies.
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Every row is a public regulatory disclosure — a Form 4 filing with the SEC — collected within minutes of being published. We don’t take company submissions and we don’t edit the numbers; the only thing we add is the rating and the reasoning behind it.
Sometimes. A insider buying with their own money is one of the few honest signals in the market, but plenty of purchases are routine — small top-ups, scheme allocations, or a well-paid executive rounding out a holding. That’s what our six-point check is for: it separates the conviction buys from the housekeeping, and shows you which is which.
The pipeline runs every 15 minutes through the trading day, so a new disclosure appears here shortly after it’s filed. Company stats refresh daily.
Yes — that’s what the app is for. Follow Aclarion, Inc. and you’ll get a push the moment a insider files, with the full analysis attached, plus alerts if the price moves after a buy you’re following.
No. ddbx rates the conviction behind insider buys and shows the reasoning. It’s information, never a recommendation, and never a guarantee. What you do with it is your call.